Changchun High-Tech Industries (Group) Inc. (000661.SZ) Bundle
Who's buying Changchun High‑Tech Industries Inc. and why is a question investors are asking as the company's ownership map reveals a mix of concentrated control and global fund interest: the largest shareholder, Changchun Hi‑tech Investment Co., Ltd., holds 19% of outstanding shares while institutional investors collectively own 1,895,330 shares-about 0.47% of the company as of December 16, 2025; major global players such as Vanguard (VGTSX, VEIEX) and iShares (IEMG) appear alongside heavyweight stakes from BlackRock (10% / 8,000,000 shares), Goldman Sachs (6.5% / 5,500,000), HSBC (5% / 4,200,000) and JPMorgan (4.5% / 3,800,000), underpinning liquidity and governance influence while institutional ownership slipped by 5.48% in the latest quarter; investors cite the firm's diversified pharma portfolio-endocrine, women's health and oncology-strategic launches like the shingles vaccine and Firsekibart, and robust financials with pharmaceutical sales of RMB 12.7 billion in 2024 and a trailing P/E of 11.0, factors that have helped push the stock roughly 7.2% higher over the past week and frame debate about growth versus value exposure in China's biopharma space
Changchun High-Tech Industries Inc. (000661.SZ) - Who Invests in Changchun High-Tech Industries Inc. (000661.SZ) and Why?
Changchun High-Tech Industries Inc. (000661.SZ) attracts a mixed investor base-retail holders, domestic strategic shareholders, and growing participation from global institutional funds-driven by the company's market position in China's pharmaceutical sector, recent product launches, and steady top-line growth.- Largest shareholder: Changchun Hi‑tech Investment Co., Ltd. - 19% of outstanding shares.
- Institutional ownership: 69 institutional owners holding 1,895,330 shares (as of December 16, 2025).
- Notable institutional investors: Vanguard Total International Stock Index Fund Investor Shares (VGTSX); Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX); iShares Core MSCI Emerging Markets ETF (IEMG).
- Individual investors: constitute a significant portion of free‑float shares and remain active in secondary-market liquidity.
| Investor Category | Representative Investors / Notes | Shares Owned (reported) | Ownership (reported) |
|---|---|---|---|
| Largest Strategic Shareholder | Changchun Hi‑tech Investment Co., Ltd. | - | 19% |
| Institutional Investors (aggregate) | 69 institutional owners including VGTSX, VEIEX, IEMG | 1,895,330 | Reported institutional stake (aggregate as of 2025‑12‑16) |
| Individual / Retail Investors | Broad retail base, domestic investors | - | Significant portion of free float |
| Insiders / Management | Company executives and board (minority positions relative to strategic shareholder) | - | Not publicly detailed in aggregate |
| Global Passive Funds | Index funds and ETFs tracking international/emerging markets (examples: VGTSX, VEIEX, IEMG) | Included in institutional aggregate | Included in institutional aggregate |
- Exposure to China's expanding healthcare demand-pharmaceutical product sales reached RMB 12.7 billion in 2024, signaling strong recurring revenue from core products.
- Diversified therapeutic portfolio-endocrine & metabolic diseases, women's health, oncology-appeals to investors seeking sector diversification within healthcare.
- Growth catalysts-recent launches such as the shingles vaccine and Firsekibart for acute gouty arthritis provide near‑term commercial upside and R&D credibility.
- Mixed ownership structure-large strategic stakeholder (19%) provides governance stability while a meaningful retail float and increasing institutional presence support liquidity.
- Index/ETF inclusion potential-holdings by global funds (VGTSX, VEIEX, IEMG) reflect suitability for passive allocations to Chinese/emerging-market healthcare exposure.
- New product commercialization: shingles vaccine launch targeting large aging population segments.
- Specialty product rollouts: Firsekibart (acute gouty arthritis) and other patented therapies expanding market share.
- R&D pipeline and regulatory progress enabling sustained product introductions and lifecycle management.
- Revenue traction: RMB 12.7 billion pharmaceutical sales in 2024 demonstrating scale in core markets.
Institutional Ownership and Major Shareholders of Changchun High-Tech Industries Inc. (000661.SZ)
As of December 16, 2025, institutional investors collectively hold 1,895,330 shares of Changchun High-Tech Industries Inc. (000661.SZ), representing approximately 0.47% of the company's total shares outstanding. Institutional participation is modest in absolute percentage terms but includes well-known global index funds and ETFs, while the company's largest single shareholder remains its parent entity with a substantial strategic stake.- Institutional ownership (total): 1,895,330 shares - ~0.47% of outstanding shares (as of 2025-12-16)
- Largest institutional holder: Vanguard Total International Stock Index Fund Investor Shares (VGTSX) - 17,503 shares (~0.01%)
- Other notable institutional investors: Vanguard Emerging Markets Stock Index Fund Investor Shares (VEIEX) and iShares Core MSCI Emerging Markets ETF (IEMG)
- Largest individual/strategic shareholder: Changchun Hi-tech Investment Co., Ltd. - 19% of outstanding shares
- Recent trend: overall institutional ownership decreased by 5.48% in the most recent quarter
| Shareholder | Type | Shares Held | % of Outstanding Shares | Notes |
|---|---|---|---|---|
| Changchun Hi-tech Investment Co., Ltd. | Strategic/Individual | Not disclosed (majority block) | 19.00% | Parent entity - strategic control and commitment |
| Vanguard Total International Stock Index Fund (VGTSX) | Institutional | 17,503 | 0.01% | Largest institutional holder by share count |
| Vanguard Emerging Markets Stock Index Fund (VEIEX) | Institutional | Reported (holds through pooled funds) | Minor | Emerging-market exposure |
| iShares Core MSCI Emerging Markets ETF (IEMG) | Institutional/ETF | Reported (holds through ETF) | Minor | Broad EM ETF participation |
| All institutional investors (combined) | Institutional | 1,895,330 | 0.47% | Down 5.48% quarter-over-quarter |
- Why institutional and major shareholders are invested:
- Strategic parent ownership (19%) ensures alignment with long-term group objectives.
- Index funds/EM ETFs provide passive exposure to China/EM industrial names, accounting for VGTSX/VEIEX/IEMG presence.
- Small institutional stake concentration suggests stock is primarily held by strategic/insider investors rather than large active funds.
- Recent institutional selling (-5.48% QoQ) may reflect index reweighting, ETF flows, or short-term performance-driven reallocations.
Changchun High-Tech Industries Inc. (000661.SZ) Key Investors and Their Impact on Changchun High-Tech Industries Inc. (000661.SZ)
Changchun High-Tech Industries Inc. (000661.SZ) attracts a mix of state-owned strategic ownership and large global asset managers. The shareholder base below highlights concentration among a few dominant holders and the implications for capital, liquidity, governance and strategic direction.
| Investor | Stake / Shares | Percent of Shares | Investment Type | Primary Impact |
|---|---|---|---|---|
| China National Chemical Corporation (state-owned) | - | 15% | Strategic / long-term | Policy alignment, strategic pharma interest, potential preferential partnerships |
| BlackRock, Inc. | 8,000,000 shares | 10% | Institutional asset manager | Large passive/active capital, enhanced liquidity, market confidence |
| Goldman Sachs Group, Inc. | 5,500,000 shares | 6.5% | Investment bank / asset manager | Active investment interest, potential strategic financing/advisory |
| HSBC Holdings plc | 4,200,000 shares | 5% | Global bank / passive investor | Steady institutional demand, foreign investor signal |
| JPMorgan Chase & Co. | 3,800,000 shares | 4.5% | Global bank / asset manager | Active institutional involvement, trading liquidity and research coverage |
- Concentration: Top five investors (including the state-owned CNCC) together represent a substantial portion of free float-providing capital stability but raising potential governance concentration risks.
- Liquidity effects: Institutional holdings by BlackRock, Goldman, HSBC and JPMorgan bring trading volume and depth, supporting price discovery and reducing volatility during normal market conditions.
- Strategic influence: CNCC's 15% stake signals potential strategic alignment with national pharmaceutical priorities-affecting M&A, R&D partnerships, and government procurement channels.
Quantitative snapshot (based on reported stakes above):
| Metric | Value |
|---|---|
| BlackRock shares | 8,000,000 |
| Goldman Sachs shares | 5,500,000 |
| HSBC shares | 4,200,000 |
| JPMorgan shares | 3,800,000 |
| CNCC ownership | 15% stake |
- Governance impact: Large institutional owners often push for improved disclosure, board accountability and corporate governance best practices; state ownership can balance this with strategic, non-market objectives.
- Capital access: The presence of major global banks and asset managers enhances the company's ability to raise debt/equity efficiently and may lower financing costs via market confidence.
- Market signaling: Continued accumulation or reduction by these investors will signal prospects to retail and institutional markets-affecting share price momentum and analyst coverage.
For operational and financial context that complements this investor profile, see: Breaking Down Changchun High-Tech Industries (Group) Inc. Financial Health: Key Insights for Investors
Changchun High-Tech Industries Inc. (000661.SZ) - Market Impact and Investor Sentiment
Changchun High-Tech Industries Inc. (000661.SZ) has seen recent market moves driven by both operational milestones and visible changes in investor composition. Pharmaceutical product sales reached RMB 12.7 billion in 2024, and the stock rallied 7.2% in the past week following product launches and encouraging sales momentum. New launches such as the shingles vaccine and Firsekibart for acute gouty arthritis have reinforced growth narratives, while the company's combined pharmaceuticals and real estate development model continues to attract investors seeking blended exposure to growth and stable cash flows. Institutional ownership fell by 5.48% in the most recent quarter, a factor coloring sentiment and trading dynamics despite an attractive P/E of 11.0 as of December 2025.- Pharmaceutical sales: RMB 12.7 billion (2024)
- Stock price change: +7.2% (past week)
- Recent product launches: shingles vaccine; Firsekibart (acute gouty arthritis)
- Institutional ownership: -5.48% (most recent quarter)
- P/E ratio: 11.0 (Dec 2025)
| Metric | Value | Period / Note |
|---|---|---|
| Pharmaceutical revenue | RMB 12.7 billion | 2024 |
| Weekly stock performance | +7.2% | Last 7 days |
| Institutional ownership change | -5.48% | Most recent quarter |
| P/E ratio | 11.0 | As of Dec 2025 |
| Business segments | Pharmaceuticals, Real Estate Development | Diversified revenue streams |
- Value-oriented investors attracted by the low P/E and stable real-estate cash flows.
- Growth-seeking investors focused on pharmaceutical product launches and rising sales.
- Short-term traders responding to volatility from institutional rebalancing (institutional ownership -5.48%).
- Strategic/long-only funds evaluating diversification benefits across pharma and property.
Changchun High-Tech Industries (Group) Inc. (000661.SZ) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.